Comparing steroid, antifungal, or both for ABPA
Treatments studied
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This trial compares three treatments for ABPA: a steroid (prednisolone), an antifungal (itraconazole), or both together. It aims to find which works best for controlling symptoms and preventing flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ABPA (allergic bronchopulmonary aspergillosis) and asthma.
- Your ABPA is either newly diagnosed and causing symptoms, or it has recently gotten worse (lasting at least 2 weeks).
- You have not had 3 or more ABPA flare-ups in the last 18 months.
- You have not used high-dose steroids or certain antifungals for more than 2 weeks in the last 3 months.
- You do not have another serious medical condition (like uncontrolled diabetes, kidney failure, liver disease, or heart failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares itraconazole taken by mouth alone versus itraconazole plus steroid pills in people who have a mix of two Aspergillus lung conditions. It aims to see which approach works better to control symptoms and lung changes caused by Aspergillus infection.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
This study tests if biologic drugs are safe and effective for people with allergic bronchopulmonary aspergillosis (ABPA) who also have severe asthma. It may help if you've had an asthma attack in the past year.
This study looks at how the presence of fungus in lung samples relates to the long-term outlook for people with allergic bronchopulmonary aspergillosis (ABPA). It aims to help doctors better understand the disease and guide treatment.
This study looks at how well the drug tezepelumab works in treating allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a common fungus. It may help reduce asthma symptoms and flare-ups in people with severe asthma related to ABPA.
This study tests whether benralizumab, a biologic medicine, works well in real-world settings for people with severe asthma caused by an allergic reaction to a common mold called Aspergillus. You may qualify if you have hard-to-control asthma despite strong medications and recent asthma flare-ups.
Hear when a new Allergic Bronchopulmonary Aspergillosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.